Results of annual general meeting declared by Universal IbogaineAround 6 million Canadians will meet addiction during their lifetime, according to the Canadian Mental Health Association. With 22,828 total fatalities in Canada over a five year period, the opioid crisis marks one of the most extreme types of addiction. The fatality rate is rising year to year. Universal Ibogaine constantly working on a mission to transform addiction treatment using ibogaine through a planned Canadian clinical trial focused on opioid use disorder. Recently universal ibogaine declared the results and Investors are very happy with the latest press release of $IBO as all resolutions were passed by the requisite majority of shareholders at its annual general meeting which was held on October 3, 2022 in Vancouver. The shareholders also approved the re-appointment of Deloitte LLP as auditors of the Company for the ensuing year, and approved the Company’s 2021 Stock Option Plan, the Company’s 2022 Equity Incentive Compensation Plan and the Company’s 2022 Stock Option Plan.
TSXV:IBO
universalibogaine.com/universal-ibogaine-announces-results-of-annual-general-meeting/
Universal ibogaine plans to transform addiction management, while developing ibogaine as a central component of innovation for addiction treatment.
· Universal ibogine engaged in acquiring an active addiction treatment center in Canada to perfect the wrap-around treatments and roll out ibogaine once approved in Canada. Also partnering with Canadian First Nations to investigate treatment possibilities on sovereign indigenous territories.
· Universal ibogaine has developed a state of the art holistic addiction treatment protocol at its Kelburn clinic that, when paired with planned ibogaine detox protocol. It is also intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
Universal ibogaine , one of the versatile bio technology companies, was created with the goal of medicalizing ibogaine for addiction treatment in Canada and then globally.
TSX-V:IBO
